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ABSTRACT
Objective To investigate the efficacy of a programme of
manual therapy and exercise treatment compared with
placebo treatment delivered by physiotherapists for
people with chronic rotator cuff disease.
Design Randomised, participant and single assessor
blinded, placebo controlled trial.
Setting Metropolitan region of Melbourne, Victoria,
Australia.
Participants 120 participants with chronic (>3 months)
rotator cuff disease recruited through medical
practitioners and from the community.
Interventions The active treatment comprised a manual
therapy and home exercise programme; the placebo
treatment comprised inactive ultrasound therapy and
application of an inert gel. Participants in both groups
received 10 sessions of individual standardised
treatment over 10 weeks. For the following 12 weeks, the
active group continued the home exercise programme
and the placebo group received no treatment.
MainoutcomemeasuresTheprimaryoutcomeswerepain
and function measured by the shoulder pain and
disability index, average pain onmovement measured on
an 11 point numerical rating scale, and participants’
perceived global rating of overall change.
Results 112 (93%) participants completed the 22 week
trial. At 11 weeks no difference was found between
groups for change in shoulder pain and disability index
(3.6, 95% confidence interval −2.1 to 9.4) or change in
pain (0.7, −0.1 to 1.5); both groups showed significant
improvements. More participants in the active group
reported a successful outcome (defined as “much
better”), although the difference was not statistically
significant: 42% (24/57) of active participants and 30%
(18/61)ofplaceboparticipants(relativerisk1.43,0.87to
2.34). The active group showed a significantly greater
improvement in shoulder pain and disability index than
did the placebo group at 22 weeks (between group
difference 7.1, 0.3 to 13.9), although no significant
difference existed between groups for change in pain
(0.9, −0.03 to 1.7) or for the percentage of participants
reporting a successful treatment outcome (relative risk
1.39, 0.94 to 2.03). Several secondary outcomes
favoured the active group, including shoulder pain and
disability index function score, muscle strength,
interference with activity, and quality of life.
ConclusionAstandardisedprogrammeofmanualtherapy
and home exercise did not confer additional immediate
benefits for pain and function compared with a realistic
placebo treatment that controlled for therapists’ contact
in middle aged to older adults with chronic rotator cuff
disease. However, greater improvements were apparent
at follow-up, particularly in shoulder function and
strength, suggesting that benefits with active treatment
take longer to manifest.
Trial registration Clinical trials NCT00415441.
INTRODUCTION
Shoulder disorders are a common cause of persistent
musculoskeletal morbidity,
12 particularly in the mid-
dle to older age groups.
3 Pain and compromised
shoulder function have a substantial impact on tasks
essential to daily living, as well as on sleep.
4 Shoulder
disorders are a common reason for seeking medical
care and may require surgical intervention in up to
28% of cases.
5-7 Shoulder disorders can thus lead to
considerable disability, reduced health related quality
of life, absenteeism from work, and use of healthcare
resources.
489
Although definitions of different diagnostic cate-
gories of shoulder pain are controversial, a large pro-
portion of shoulder problems can be classified as
“rotator cuff disease,” the most common cause of
shoulder pain in primary care.
10 The term, or its var-
iants such as impingement syndrome, may include a
spectrum of pathologies of rotator cuff disease (such
as subacromial bursitis, partial rotator cuff tears, and
bicipital tendinosis), but they are characterised clini-
cally by pain with abduction (painful arc) and signs of
impingement.
11 Although standard criteria have not
been established for use in clinical trials, most trials
thathaveassessedinterventionsforrotatorcuffdisease
have used variations of these features to select their
study populations.
12-14 Rotator cuff disease differs
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painsuchasadhesivecapsulitis,osteoarthritis,andcal-
cific tendinitis, which are known to have different pre-
sentations, underlying causes, prognoses, and
responses to treatment.
A combination of modalities of physiotherapy, such
as manual therapy and exercise, is often used in the
managementofrotatorcuffdisease.
15Theseaimtocor-
rect modifiable physical impairments thought to con-
tribute to pain and dysfunction rather than to treat the
specific pathology. These impairments include rotator
cuff and scapular muscle weakness and dysfunction,
tightnessoftheposteriorcapsuleandothersofttissues,
and postural abnormalities.
16 Little conclusive evi-
dence supports or refutes the efficacy of different
physiotherapy programmes given the variable metho-
dological quality of the trials, including a lack of pla-
cebo control and the fact that many tested a single
modality despite multimodality treatment being the
most common way in which physiotherapists treat
shoulder disorders.
1317-20 The conclusions and recom-
mendations of recent systematic reviews support the
need for further clinical trials.
21-23 The primary aim of
this trial was, therefore, to determine whether a
10 week programme of standardised manual therapy
and home exercise delivered by a physiotherapist
improves shoulder pain and function more than pla-
cebo treatment does in people with chronic rotator
cuff disease.
METHODS
Participants
Between March 2004 and November 2007, we
recruited people with chronic rotator cuff disease
through medical practitioners and from the commu-
nity through print and radio media. We required all
participants to have a plain radiograph of the shoulder
to check for exclusions (see below), and we required
potential participants recruited directly from the com-
munity to have the diagnosis of rotator cuff disease
confirmed by a medical practitioner. After an initial
screen by telephone, an experienced physiotherapist
(EW or SC) did a physical examination. Inclusion cri-
teria were age over 18 years, shoulder pain for more
thanthreemonths,severityofpainonmovementrated
greater than 3/10 on an 0-10 numerical rating scale,
pain on active abduction or external rotation, and a
positive quick test for shoulder impingement.
24 Exclu-
sion criteria were resting severity of shoulder pain
greaterthan7/10;reasontosuspectacompleterotator
cufftear(forexample,substantialshoulderweakness,a
positive drop-arm sign, or a high riding humerus on
plain radiograph); previous shoulder surgery; radio-
logical evidence of shoulder osteoarthritis, calcifica-
tion, or previous fracture; systemic pathology
including inflammatory joint disease or neoplastic dis-
orders; more than 50% restriction of passive range of
motion in two or more planes; shoulder pain referred
from vertebral structures diagnosed by spinal clearing
tests
25;symptomsofcomplexregionalpainsyndrome;
active intervention in the previous three months,
including corticosteroid injection, arthrographic dis-
tension of the glenohumeral joint with corticosteroid
and saline (hydrodilatation), or physiotherapy; anti-
inflammatory drugs in the previous two weeks; and
inability to understand written and spoken English.
Procedures
We did a randomised, participant and assessor
blinded, controlled trial. Participants had a baseline
assessment and were randomised in permuted blocks
of six and eight, stratified by treating physiotherapist,
toreceiveeitheractivemanualtherapyandhomeexer-
cise treatment or placebo treatment according to a
computer generated table of random numbers created
by the study biostatistician (AF). Allocations were
sealed in opaque and consecutively numbered envel-
opeskeptinacentrallockedlocation.Anindependent
administrator opened the envelopes in sequence and
then revealed the group allocation to the relevant
physiotherapist by facsimile just before the participant
presented for treatment.
Interventions
Details about the interventions have been published
previously.
26 Fourteen musculoskeletal physio-
therapists (all with more than four years of relevant
clinical experience) from 12 centres (two public hospi-
tal physiotherapy departments and 10 private physio-
therapy clinics) were trained to provide both
interventions. Therapists attended initial training ses-
sions and were given a detailed treatment manual. We
couldnotblindthetherapiststotreatmentgroup.Both
interventionswerestandardisedandcomprisedindivi-
dualsessionstwiceweeklyforthefirstfortnight,oncea
week for the next four weeks, then once a fortnight in
the last four weeks (10 visits, 30-45 minutes each). To
minimise the risk of participants meeting, appoint-
ments were scheduled at different times. We assessed
therapists’ adherenceto the protocol by completion of
a treatment log. Simple analgesia was permitted, but
participants were asked to refrain from seeking other
forms of treatment during the trial. Treatment in both
groups was provided at no cost to the participant.
We based the active intervention on the literature
andontheresultsofa formalwrittensurveyof16Aus-
tralianmusculoskeletalphysiotherapistswithexpertise
intreatingshoulderconditions.
27Theinterventionwas
directed at improving dynamic scapular control,
strengthening scapular stabiliser and rotator cuff mus-
cles, improving shoulder and thoracic posture, and
increasing range of motion of thoracic extension. The
intervention had five components comprising soft tis-
suemassage,passivemobilisationoftheglenohumeral
joint, scapular retraining and postural taping, spinal
mobilisation (to assist in improving shoulder girdle
posture and spinal range of motion), and home exer-
cises (table 1).
26 We incorporated behavioural strate-
gies,includingeducation,goalsetting,motivation,and
positive reinforcement. Home exercises were done
daily, except during the first week of treatment when
exercises were completed twice daily (web appendix).
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active group were instructed to maintain their daily
home exercise programme for 12 weeks.
Participants in the placebo group attended the same
number of treatments as did those in the active treat-
mentgroupbutreceivedshamultrasoundtherapyand
light application of a non-therapeutic gel to the
shoulder region for 10 minutes each. They received
no instruction in exercise techniques and no manual
therapy. We have successfully used this same placebo
protocol in previous studies.
28-30 During the 12 week
follow-up period, placebo participants did not receive
any intervention and were not instructed to do any
home exercises.
Outcome measures
The same blinded assessor (EW) evaluated all partici-
pants at baseline, at 11 weeks (at the conclusion of the
supervised active or placebo intervention), and at
22 weeks after randomisation. Baseline demographic
information was collected, and participants rated their
expectation of a beneficial effect of active physio-
therapy treatment on an ordinal scale from 1 to 5,
with higher scores indicating higher expectations.
The primary outcomes were the shoulder pain and
disability index (SPADI), average pain on movement
assessed by a numerical rating scale, and participants’
perceived global rating of change overall. The
shoulder pain and disability index is a self adminis-
tered, shoulder specific index consisting of 13 items
divided intotwo subscales—pain(fiveitems) andfunc-
tion (eight items)—with responses to each item
recorded on a 10 point scale.
31-33 We calculated a
total shoulder pain and disability index score by sum-
ming the subscales and then averaging for a score out
of 100 (higher scoresindicate more pain/dysfunction).
We measured participants’ overall assessment of
average pain on movement and pain at rest in the pre-
vious week by separate 11 point numerical rating
scales(0to10)numberedin1cmintervals.
34Themini-
mal clinically important difference for shoulder pain
on movement measured on this scale is 1.1 units.
34
The amount of weakness, stiffness, and interference
with activities of daily living over the previous week
were similarly measured.
Participants’perceivedglobalratingofchangeover-
all and in pain, strength, and stiffness (from baseline)
wererecordedonseparatefivepointLikert-typescales
(1=much worse, 2=slightly worse, 3=no change,
4=slightly better, 5=much better).
35 We defined a suc-
cessful outcome for each a priori as “much better” on
the rating scale.
We measured generic health related quality of life
with the Medical Outcomes Study 36-item short form
(SF-36) (eight subscales scaled from 0-100, in which a
higherscore representsbetterhealth, summarisedinto
physical function and mental health scales) and the
assessment of quality of life (AQoL) instrument.
3637
The latter instrument comprises 15 items covering
five dimensions (illness, independent living, social
relationships, physical senses, and psychological
wellbeing).
3839 Item responses are all ordinal scales
with four levels per item. Scores are scaled from
−0.04 (worse than death) to 1.00 (perfect health).
We measured isometric shoulder strength of the
symptomaticlimb forshoulderabduction and internal
and external rotation with the Nicholas Manual Mus-
cletester(Lafayette,USA).Forabduction,participants
were in supine position with the shoulder in 90° of
abductionandthedynamometerpositionedonthelat-
eral surface of the distal humerus. Measurements of
external and internal rotation were made in sitting
position with the arm by the side against a folded
towel with the elbow flexed to 90° and the dynam-
ometer positioned on the distal forearm. After a
demonstration and one warm-up trial, participants
were asked to push as hard as they possibly could
against the dynamometer for four seconds while the
testerprovidedconsistentloudverbalencouragement.
The mean reading of three maximal contractions was
taken.Reliabilityisexcellentinourlaboratory(12peo-
ple with rotator cuff disease tested by two examiners
twicetwotofourdaysapart:intraclasscorrelationcoef-
ficient (2,3) values ≥0.89 for intra-rater reliability of
each examiner and ≤0.90 for inter-rater reliability
27).
We measured participants’ adherence to treatment
by recording the number of physiotherapy sessions
attended (out of a maximum of 10). Participants in
the active group also completed a daily log book to
record the number of home exercise sessions
Table 1 |Components of active physiotherapy intervention
Treatment component Description Dosage
Soft tissue massage Anterior and posterior shoulder tissues, in supine and side-lying positions respectively 6 minutes each position
Glenohumeral joint mobilisation Anteroposterior and inferior joint glides in supine position with shoulder at 45° and 90°
abduction respectively
4×30 seconds each position
Thoracic spine mobilisation (T1-8) In prone position, using central posteroanterior technique Grade IV on each level: 4 minutes in total
Cervical spine mobilisation (C5-7) In prone position using unilateral posteroanterior technique on both sides Grade IV on each level: 4 minutes in total
Scapular retraining In side-lying position, therapist passively moves shoulder through range from elevation/
protractiontoretraction/depression,thenassistedbyparticipant,thenindependentlyby
participant; isometric holds in retraction/depression
Weeks 1 and 2 only; 15 repetitions × 5r e p e t i t i o n sw i t h
10 second holds
Postural taping Taping of shoulders and scapula to encourage scapular retraction and depression and
thoracic extension
Continuous (day and night) for two weeks; re-applied after
one week by therapist
Home exercises Supervised and done as home programme Homeprogramme:twicedailyinfirsttwoweeks;onceaday
thereafter
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ventions in both groups were recorded in a log book.
To measure the success of blinding, we asked partici-
pants to indicate which treatment they believed they
had received at the 22 week assessment.
Sample size
We calculated sample size on the basis of ability to
detect a 10 point difference in improvement in total
shoulder pain and disability index score, previously
reported to indicate a clinically important improve-
ment (or worsening) of shoulder function.
32 Applying
power calculations appropriate for analysis of covar-
iance (adjustingfor baseline shoulderpain and disabil-
ity index score), to detect a difference in 11 week
shoulder pain and disability index score of 10 units
assuming a common between participant standard
deviation of 27 and a baseline to 11 week correlation
of 0.45 (from our pilot study
27), we calculated that we
needed 91 participants per group to achieve 80%
power at a two sided 5% significance level.
Asrecruitmentwasmuchslowerthananticipated,an
independentstatisticiannotpreviouslyassociatedwith
the trial did a blinded assessment of the between parti-
cipant standard deviation and baseline to 11 week cor-
relation after 46 patients had completed follow-up.
These were more favourable than initially planned
(SD=21, r=0.60), and we revised the total trial sample
size downwards to 60 participants per arm to maintain
80% power to detect a difference of 10 units with these
revised parameters.
Data analysis
We did analyses on an intention to treat principle,
using all randomised participants. We replaced miss-
ing data by the last score carried forward. For out-
comes measured using an essentially continuous
scale, we compared differences in mean change from
baseline to each time point between groups by using
linear regression modelling with adjustment for base-
linelevelsoftheoutcomemeasure.Wecheckedmodel
assumptions by standard diagnostic plots.
We dichotomised participants’ measures of per-
ceivedglobalchangeafteractiveorplacebotreatments
into successful (much better) or unsuccessful (slightly
better,nochange,slightlyworse,andmuchworse)out-
come. We compared the percentage of successful out-
comesbetweengroupsbycalculatingrelativerisksand
their 95% confidence intervals at each time point with
log binomial regression.
40
Wecalculatedanindextoassessthesuccessofblind-
ingaftertreatment.
41Thisindextakesthevalueonefor
completeblindingand zerofor completelackofblind-
ing.
RESULTS
We recruited 120 participants (59 active, 61 placebo),
and 112 (54 active, 58 placebo; 93%) completed the
22 week trial. Figure 1 shows the flow of participants
through the trial. Two participants, both from the
active group, withdrew before completing the
10 week intervention. A further six participants (three
active,threeplacebo)withdrewbeforethe22weekfol-
low-up. Demographic and clinical characteristics of
the eight participants who withdrew from the study
did not differ from those of the 112 who remained
(data not shown).
Thegroupsweresimilaratbaselinefordemographic
and clinical characteristics, although the median dura-
tion of symptoms seemed to be longer in the active
group (table 2). The participants’ expectation of treat-
mentoutcomesforactivephysiotherapywassimilarin
the two groups (P=0.79); 95/105 (90%) participants
who provided this information expected a moderate
or large beneficial effect.
Efficacy analysis
Immediately after treatment (11 weeks)
Both groups showed significant improvements imme-
diately after treatment (11 weeks). However, we found
Allocated to placebo intervention (n=61) Allocated to active intervention (n=59)
Assessed for eligibility by phone (n=1380)
Did not meet inclusion criteria or not
interested in participating (n=942)
Assessed for eligibility by physical screening (n=438)
Randomised (n=120)
Excluded (n=318):
  Did not meet inclusion criteria (n=313)
  Refused to participate (n=5)
Enrolment: patients
Allocation: patients
Physiotherapists (n=11), centres (n=9)
No of patients treated by each physiotherapist:
  median=5 IQR=4.0-7.5, min=1, max=10
No treated at each centre:
  median=5, IQR=4.0-7.0, min=2, max=19
Physiotherapists (n=14), centres (n=12)
No of patients treated by each physiotherapist:
  median=4, IQR=1.3-5.8, min=1, max=11
No treated at each centre:
  median=4, IQR=1.0-7.5, min=1, max=16
Allocation:
physiotherapists
Lost to week 11 assessment (n=0)
Discontinued intervention (n=0)
Lost to week 11 assessment:
  Unable to contact (n=1)
Discontinued intervention:
  Concomitant injury (n=1)
Week 11 assessment:
patients
Lost to week 22 assessment (n=3):
  Unable to contact (n=2)
  Withdrew (n=1)
Lost to week 22 assessment (n=3):
  Unable to contact (n=2)
  Moved overseas (n=1)
Week 22 assessment:
patients
10 x individual treatment sessions 10 x individual treatment sessions
Treatment phase
No exercises Daily home exercises
Follow-up phase
Analysed (n=61)
Excluded from analysis (n=0)
Analysed (n=59)
Excluded from analysis (n=0)
Analysis: patients
Fig 1 | Flow of participants through study. IQR=interquartile range
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mary outcomes of changes in shoulder pain and dis-
ability index total score (3.6, 95% confidence interval
−2.1 to 9.4) and pain on movement (0.7, −0.1 to 1.5)
(table 3, fig 2). More participants in the active group
reported an overall successful outcome (defined as
“much better”), although the difference was not statis-
tically significant: 42% of active participants and 30%
of placebo participants (relative risk 1.43, 95% confi-
dence interval 0.87 to 2.34) (table 4).
With regards to the secondary outcomes, the active
group showed significantly greater improvements in
both self reported and objective measures of strength
(tables 3 and 4). We found no significant differences
between treatment groups for other outcomes, includ-
ing changes in health related quality of life.
Twenty-two week follow-up
The active group showed a significantly greater
improvement in shoulder pain and disability index
total score at 22 weeks than did the placebo group
(mean between group difference 7.1, 0.3 to 13.9)
(table 3, fig 2). However, this was not accompanied
by significant differences between the active and pla-
cebo groupsfor changein painonmovement (table 3,
fig 2) or for the percentage of participants reporting an
overallsuccessful treatmentoutcome(table 4).Within
group changes in the primary outcomes remained sig-
nificant at the 22 week follow-up (all P<0.001).
Severalsecondaryoutcomesalsoshowedbenefitsin
favour of the active group. We saw greater improve-
ments in shoulder pain and disability index function
score, muscle strength, interference with activity, and
health related quality of life as measured by the assess-
ment of quality of life instrument (tables 3 and 4).
Other analyses
The results immediately after treatment and at follow-
up were essentially unaltered when reanalysed
comparing the active group participants who reported
more than 50% adherence to the home exercise pro-
gramme (n=35) with the placebo participants; as a
completers’ analysis without replacing the missing
values; controlling for duration of symptoms by add-
ingatermintheregressionanalysis;andusinggeneral-
ised estimating equations to fit population averaged
models (data not shown).
Adherence, adverse events, and co-interventions
Fifty-two (91%) of 57 participants in the active group
and57/61(93%)ofthoseintheplacebogroupattended
all 10 physiotherapy treatment sessions. The number
of sessions attended by the remainder ranged from
three to nine with a mean of 4.8 (SD 2.7) in the active
groupandfromonetosevenwithameanof6.0(3.5)in
the placebo group. Of the active group participants
who completed the exercise diaries (52/57 during the
interventionperiodand39/55inthefollow-upperiod),
the mean self reported completion of home exercise
sessions was 57.2 (SD 15.7, 82%) during the inter-
vention period and 49.0 (20.3, 70%) during the fol-
low-up period.
Duringtheinterventionperiod,17/55 (31%)partici-
pants in the active group reported adverse events.
These comprised increased short term pain during or
after the treatment session (n=3), increased short term
painwiththehomeexercises(12),andmildirritationto
the tape used for postural taping (2). In the placebo
group, 5/61 (8%) reported adverse events comprising
increasedshort term painduringor afterthe treatment
session. During the follow-up period, adverse events
were reported only by the active group (7/49, 14%)
and comprised increased short term pain with the
home exercises.
Use of analgesics and non-steroidal anti-inflamma-
torydrugswassimilarintheactiveandplacebogroups
over both the intervention period (analgesics: 11/55
(20%) active v 14/61 (23%) placebo; non-steroidal
anti-inflammatories: 12/55 (22%) v 13/61 (21%); both
P>0.05) and the follow-up period (analgesics: 8/49
(16%) v 8/55 (15%); non-steroidal anti-inflammatories
6/49 (12%) v 8/55 (15%); both P>0.05).
During the intervention period, one (2%) placebo
participant received a cortisone injection into the
shoulder. During the follow-up period, two (4%) parti-
cipants in the active group received a cortisone injec-
tion into the shoulder and one (2%) participant in the
placebo group received acupuncture treatment.
Success of blinding
In the active group, 32/55 (58%) participants correctly
identifiedtheirtreatmentgroup at 11weekscompared
with21/61(34%)participantsinthe placebogroup;15
(27%) participants in the active group were uncertain
which treatment they had received compared with 27
(44%) participants in the placebo group; and 8 (15%)
participants in the active group incorrectly identified
their treatment group compared with 13 (21%) partici-
pants in the placebo group. The blinding index was
0.70 (bootstrap 95% confidence interval 0.58 to 0.82),
Table 2 |Demographic and clinical characteristics of active
and placebo groups. Values are numbers (percentages)
unless stated otherwise
Characteristic Active n=59 Placebo n=61
Mean (SD) age (years) 59.3 (10.1) 60.8 (12.4)
Median (interquartile range)
duration of symptoms (months)
24 (6-54) 14 (6-24)
Mean (SD) height (cm) 169.0 (9.1) 167.5 (10.8)
Mean (SD) body mass (kg) 79.5 (13.5) 78.9 (15.9)
Mean (SD) body mass index (kg/
m
2)
27.8 (4.4) 27.9 (4.8)
Male sex 34 (58) 30 (49)
Affected shoulder (right:left) 35:24 38:23
Dominant side affected 38 (64) 42 (69)
Previous treatment: 29 (49) 35 (57)
Physiotherapy 20 (34) 26 (43)
Corticosteroid injection 10 (17) 15 (25)
Massage 2 (3) 1 (2)
Acupuncture 5 (8) 4 (7)
Chiropractic/osteopathy 6 (10) 6 (10)
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ness and representing a statistically significant amount
of blinding beyond that expected by chance (the value
of the blinded index is 0.5 for random guessing).
DISCUSSION
This randomised, participant and single assessor
blinded,placebocontrolledtrialevaluatedtheefficacy
of a 10 week manual therapy and home exercise pro-
gramme delivered by physiotherapists for the treat-
ment of chronic rotator cuff disease in middle aged to
older adults. Immediately after the intervention
(11weeks),thestandardisedactivetreatmentgenerally
produced similar beneficial effects on shoulder pain
and function, the primary endpoints of the trial, com-
paredwitharealisticplacebotreatmentthatcontrolled
for therapists’ contact time and the therapeutic envir-
onment.Bothgroupsimprovedbyamountsdeemedto
be clinically important,
42 and more than a third of par-
ticipants reported a successful treatment outcome.
However, we found significant differences favouring
the active group for objective and subjective measures
of muscle strength. At follow-up (22 weeks), we saw
greaterimprovementswithactivetreatmentforseveral
outcome measures. Changes in overall pain and func-
tion measured by the shoulder pain and disability
index favoured the active group, although the mean
between group difference of 7.1 was slightly below
the 8 to 13.2 points reported in the literature as being
the minimal clinically important difference.
42 Several
secondary outcomes also favoured the active group,
including shoulder pain and disability index function
score, muscle strength, interference with activity, and
quality of life.
Explanation of results
The significant improvements seen in both groups
over the 22 weeks may reflect natural recovery of the
rotator cuff disease. Although we did not include a
third“notreatment”studyarmtoascertainthis,natural
recovery is unlikely to explain the whole effect given
the long duration of symptoms, particularly in the
active group, and the moderate baseline disability of
the cohort—factors that have been associated with a
poorer prognosis.
4344 Furthermore,other clinical trials
inpatientswithchronicrotatorcuffdiseasefoundmini-
mal changes in pain or function over similar time-
frames in control groups receiving no treatment.
1419
Table 3 |Mean (SD) of groups, mean (SD) difference within groups, and mean (95% CI) difference between groups adjusted for baseline scores for outcomes
with interval data
Outcome
Groups Difference within groups*
Difference between
groups†
Week 0 Week 11 Week 22
Week 0
to week 11
Week 0
to week 22 Week 0
to week
11
Week 0 to
week 22
Active
(n=59)
Placebo
(n=61)
Active
(n=59)
Placebo
(n=61)
Active
(n=59)
Placebo
(n=61) Active Placebo Active Placebo
SPADI total (0-100) 43.3
(18.9)
43.9
(17.5)
27.2
(18.9)
31.2
(21.0)
20.9
(18.6)
28.3
(24.5)
16.1
(17.7)
12.7
(16.3)
22.4
(22.0)
15.6
(17.8)
3.6 (−2.1
to 9.4)
7.1 (0.3 to
13.9)
Pain on movement
(0-10)
4.9 (2.2) 4.9 (1.8) 2.9 (2.3) 3.6 (2.3) 2.4 (2.4) 3.3 (2.7) 2.1 (2.6) 1.3 (2.2) 2.6 (2.9) 1.6 (2.4) 0.7 (−0.1
to 1.5)
0.9 (−0.03
to 1.7)
SPADI pain (0-100) 47.8
(20.1)
48.4
(17.5)
29.8
(20.8)
33.9
(22.7)
23.0
(21.0)
31.0
(26.0)
18.0
(18.8)
14.4
(18.5)
24.8
(23.7)
17.3
(19.6)
3.2 (−3.2
to 9.6)
6.8(−0.7to
14.3)
SPADI function
(0-100)
33.6
(20.0)
33.8
(20.2)
20.0
(16.3)
25.1
(19.3)
14.1
(14.6)
22.2
(22.8)
13.6
(17.3)
8.7 (13.9) 19.6
(20.7)
11.6
(16.6)
4.7 (−0.1
to 9.5)
7.6 (1.8 to
13.4)
Pain at rest (0-10) 2.3 (1.9) 2.1 (1.8) 1.4 (1.9) 1.7 (1.9) 1.0 (2.0) 1.6 (2.1) 1.0 (2.2) 0.4 (2.0) 1.3 (2.5) 0.4 (2.5) 0.4 (−0.2
to 1.1)
0.7(−0.1to
1.4)
Weakness on
movement (0-10)
4.6 (2.4) 4.1 (2.3) 2.6 (2.3) 3.2 (2.4) 2.1 (2.3) 2.9 (2.6) 2.0 (2.6) 0.9 (2.0) 2.5 (3.0) 1.1 (2.7) 0.8 (0.05
to 1.5)
0.9 (0.1 to
1.8)
Stiffness on
movement (0-10)
3.3 (2.6) 3.4 (2.4) 2.1 (2.1) 2.6 (2.2) 1.9 (2.3) 2.6 (2.4) 1.2 (2.2) 0.8 (2.2) 1.4 (2.7) 0.8 (2.7) 0.4 (−0.2
to 1)
0.7(−0.1to
1.5)
Interference with
activity (0-10)
3.9 (2.5) 3.8 (2.3) 2.0 (1.9) 2.6 (2.1) 1.5 (1.9) 2.5 (2.6) 1.9 (2.3) 1.2 (1.9) 2.4 (2.7) 1.3 (2.4) 0.6(−0.04
to 1.2)
0.9 (0.1 to
1.7)
SF-36 physical
(0-100)
49.3
(23.4)
48.9
(25.0)
61.0
(28.1)
55.0
(27.5)
60.0
(27.2)
53.5
(29.1)
11.7
(26.5)
6.1 (17.4) 10.8
(25.0)
4.7 (22.3) 5.7 (−2.1
to 13.6)
6.3(−2.0to
14.5)
SF-36mental (0-100) 70.2
(23.4)
61.5
(21.4)
69.7
(22.1)
61.9
(20.7)
69.3
(20.4)
63.3
(21.0)
−0.6
(19.3)
0.4 (16.0) −1.0
(19.7)
1.8 (15.8) 2.1
(−3.8to8)
0.6(−5.2to
6.4)
AQoL (−0.4–1.0) 0.7 (0.1) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.0 (0.1) 0.0 (0.1) 0.0 (0.2) 0.0 (0.1) 0.0(−0.04
to 0.03)
0.0(0.04to
0.1)
Abduction strength
(kg)
7.2 (5.4) 6.2 (3.4) 8.4 (4.7) 6.7 (3.8) 8.3 (3.8) 6.5 (3.9) 1.2 (3.9) 0.5 (2.2) 1.1 (4.4) 0.4 (2.5) 1.0 (−0.1
to 2)
1.2 (0.1 to
2.3)
External rotation
strength (kg)
8.1 (4.5) 7.1 (2.6) 8.3 (3.9) 7.2 (3.0) 8.4 (3.6) 7.0 (3.0) 0.2 (3.8) 0.1 (1.4) 0.3 (4.3) −0.1 (1.9) 0.5 (−0.4
to 1.4)
0.9(−0.1to
1.9)
Internal rotation
strength (kg)
10.9 (5.5) 10.2 (4.5) 11.7 (5.2) 10.1 (4.3) 12.2 (5.3) 10.2 (4.6) 0.9 (3.1) −0.1 (2.7) 1.3 (3.4) 0.0 (2.7) 1.1(0.1to
2.1)
1.5 (0.4 to
2.5)
AQoL=assessment of quality of life; SF-36=Medical Outcomes Study 36-item short form; SPADI=shoulder pain and disability index.
*Positive change equals improvement, and positive values favour active group.
†Results from regression analyses adjusted for baseline scores.
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from the statistical phenomenon of regression to the
mean.
45 This refers to the tendency for extreme symp-
tomsatbaselinetoreturntoamoretypicalstateatfinal
assessment.Symptomsassociatedwithchronic rotator
cuffdiseasefluctuateovertime,andpatientsoftenseek
medical care or enrol in research when the symptoms
are at their worst. Furthermore, we included patients
only if their pain was worse than a specific threshold
level.Thenextchangeinsymptomsisthusmorelikely
to be an improvement.
46 However, we accounted for
regression to the mean in our statistical analyses by
adjusting for the baseline value of each variable.
47
In addition to spontaneous improvement, another
factor contributing to the total treatment effect is the
placebo effect.
48 A recent meta-analysis showed that
foractivetreatmentofchronicpainconditions(notspe-
cifically of the shoulder), spontaneous recovery contri-
butes around 10% and placebo effects around 30%.
46
Placebo effects have also been found to be greatest for
non-drug interventions and for patient reported out-
comes, particularly pain.
49 Other factors contributing
tothe placeboeffectinour trial include blindingofpar-
ticipants, a treatment protocol involving considerable
interaction with the therapist (10 individual sessions),
and the fact that most (90%) participants expected to
gain a moderate to large benefit from active treatment
(given that positive expectations are known to be asso-
ciated with improved outcomes
50). Interestingly, the
33% reduction in pain reported by the placebo group
is consistent with the 38% reduction found in the pla-
cebo group of our previous study in patients with
osteoarthritis ofthe knee, inwhichwe usedanidentical
placebo treatment and pain measure.
28
Our primary outcome measures included an assess-
mentofpainbutdidnotincludeanassessmentoffunc-
tion in isolation. The results of both the primary and
secondary outcomes suggest that active treatment did
not substantially affect pain compared with placebo.
However, evidence from the secondary outcome of
shoulder pain and disability index function score sug-
gests that shoulder function was improved to a signifi-
cantly greater extent with active treatment. Given that
our primary outcome of shoulder pain and disability
index total score includes both the pain and function
subscales, the benefits of active treatment on function
couldhavebeenmaskedatthe11weektimepointand
attenuatedatthe22weektimepoint,whenasignificant
treatmentgroupeffectwasfoundforshoulderpainand
disability index total score. Although the mean
between group difference at the latter time point (7.1
units) was slightly below the minimal clinically impor-
tant difference we used when designing the study, the
95%confidenceintervalincludesthe10unitthreshold.
This, together with the fact that the active treatment
also led to significantly greater improvements in
manysecondaryoutcomes,indicatesthatmanualther-
apy and home exercise may be beneficial particularly
over time.
Aspects of active and placebo interventions
Some debate exists in the literature about whether the
useofaplacebotreatmentasacomparatorforcomplex
interventions such as physiotherapy is appropriate.
48
The direct and indirect (placebo) effects of the therapy
havebeenarguedtobeunlikelytobedistinctanddivi-
sible, and elements that may be categorised as indirect
effects in drug trials may in fact be integral to many
non-drug interventions. Hence, using a placebo con-
trolled trial design to test an intervention such as
physiotherapy can mean that the differences between
the groups substantially underestimate the total effects
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Fig 2 | Mean (SD) shoulder pain and disability index (SPADI)
and pain on movement for active and placebo groups at
baseline, 11 weeks, and 22 weeks
Table 4 |Number (percentage) of participants reporting a successful outcome (“much better”) compared with those reporting
an unsuccessful outcome (“slightly better,”“ no change,”“ slightly worse,” or “much worse”) in both groups, with relative risks
Outcome
11 weeks 22 weeks
Active
(n=57)
Placebo
(n=61)
Relative risk
(95% CI)
Active
(n=54)
Placebo
(n=58)
Relative risk
(95% CI)
Global change overall 24 (42) 18 (30) 1.43 (0.87 to 2.34) 31 (57) 24 (41) 1.39 (0.94 to 2.03)
Global change in pain 22 (39) 20 (33) 1.18 (0.72 to 1.91) 31 (57) 25 (43) 1.33 (0.92 to 1.94)
Global change in strength 19 (33) 7 (11) 2.90 (1.32 to 6.39) 22 (41) 14 (24) 1.69 (0.97 to 2.95)
Global change in stiffness 20 (35) 13 (21) 1.65 (0.91 to 2.99) 25 (46) 18 (31) 1.49 (0.92 to 2.41)
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erroneous conclusions about efficacy. We would have
found significant beneficial effects of treatment if we
hadcomparedtheactivetreatmentwithanotreatment
control group as other studies in this area have
done.
21-23
Several aspects of the active intervention warrant
consideration. Firstly, our standardised programme
could be argued to have failed to adequately treat the
specific physical impairments that patients presented
with and that relate to shoulder pain and dysfunction.
We noted significant improvements in isometric
strengthof12-15%fortheshoulderabductorandinter-
nal rotator muscles, as well as self reported strength
gains,suggestingsomeeffect.Whethertheactivetreat-
ment also successfully tackled other physical factors
such as dynamic scapular control and thoracic posture
is unknown, as these were not measured. Limited
research shows that manual therapy techniques and
exercises similar to those used in our study can alter
shoulder and trunk biomechanics.
51
Secondly,severalparticipantsfailedtocompletemore
than half of the prescribed home exercises, particularly
during the unsupervised follow-up period. Problems
with adherence to exercise programmes are common
and reinforce the need to better incorporate strategies
to enhance adherence, particularly when formal super-
vision by therapists ceases. However, our results were
unaltered when we reanalysed the data excluding parti-
cipants who failed to complete more than 50% of the
home exercises, suggesting that levels of adherence in
this study did not unduly influence the outcome.
Thirdly, to ensure a consistent approach and allow
replication, we chose to evaluate a standardised treat-
ment programme based on common elements identi-
fiedfromoursurveyandfromtheliterature.Itdoesnot
reflect the practice of every clinician involved in the
conservative management of rotator cuff disease, and
our results cannot necessarily be generalised to other
manualtherapyandexerciseprogrammesgivendiffer-
ences in type and dosage. Furthermore, as our treat-
ment was standardised it may have been ineffective
or even inappropriate for some patients, thus worsen-
ing symptoms and attenuating the treatment effects in
theactivegroup.However,asimilarproportionofpar-
ticipants in both groups reported that they were worse
after treatment (9/57 (16%) in the active group; 7/61
(12%) in the placebo group), suggesting that this was
not the case. Further research is needed to evaluate
the efficacy of other physiotherapy protocols for
chronic rotator cuff disease and to assess treatment
that is tailored to individual patients, as occurs in clin-
ical practice.
52
Likemostothertrialsofrotatorcuffdiseasetodate,we
chose to include participants on the basis of clinical fea-
tures alone. Rotator cuff disease is known to most com-
monly affect the supraspinatus tendon,
10 but we cannot
exclude the possibility that differences existed in the
underlying structural abnormalities within our study
population, although these were likely to be equally dis-
tributed between the treatment groups. Imaging
techniques such as magnetic resonance imaging or ultra-
sonography may further improve diagnostic accuracy,
53
but these still lack sensitivity for certain pathological
features,
5455 are costly, and are generally not used in the
primary care setting. Furthermore, physiotherapy treat-
ment is not directed at the specific pathology but at the
movement dysfunction and potential underlying
mechanisms such as altered muscle function, tight struc-
tures, and poor scapular and spinal posture that have
been reported in patients with rotator cuff disease.
51
Whether better outcomes with physiotherapy could be
gained if subgroups of rotator cuff disease could be
defined and specifically treated is not known.
Comparison with previous studies
A limited number of randomised controlled trials of
physiotherapy modalities for chronic rotator cuff dis-
ease have been done, and none has tested a combined
intervention of manual therapy and exercise against a
placebo control to allow a direct comparison with our
results. The only study to use a placebo control treat-
ment (detuned laser twice weekly for six weeks) evalu-
ated a three to six month exercise programme
supervised by physiotherapists.
56 This trial found that
exercise resulted in a significant66% reduction in pain
(measured on the Neer score), which is slightly higher
than the 43% reduction in pain with our active treat-
ment. However, unlike our study, the researchers
noted little improvement in their placebo group, ren-
dering their between group differences significant.
Whether blinding of participants was successfully
achieved was not stated. Other studies have compared
exercise with arthroscopic surgery and shown similar
beneficial outcomes in patients with rotator cuff
disease.
56-58 The limited studies evaluating exercise
combined with manual therapy have used an exercise
only group as the comparator.
59-61 These have found
that the effects of exercise on both pain and function
areaugmentedwithmanualtherapy,providingaratio-
nale for evaluating a combined intervention.
Strengths and weaknesses
The strengths of our study include the rigorous study
design, adequate statistical power, excellent retention
of participants, inclusion of a placebo control, and the
use of several therapists and a variety of recruitment
sources to increase the external validity of the results.
Our study has some limitations. Therapists were not
blinded to treatment group, which is unavoidable in a
trial of this nature. However, their interaction with
patients was standardised and any bias due to non-
blindingoftherapistswouldprobablyfavourtheactive
group, which was not particularly evident in the out-
comes. Participants were blinded, but given the diffi-
cultyindesigningacredibleplaceboforphysiotherapy
interventions,blindingmaynothavebeenascomplete
as can be achieved in a drug trial in which an identical
placebo pill can be administered. However, formal
testing of the success of blinding indicated that we
achieved a moderate to high degree of blindedness,
representing a statistically significant amount of
RESEARCH
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size was reduced after a blinded interim analysis but
gave sufficient power (80%) to detect clinically mean-
ingful differences in the primary outcome. We
replaced missing values by using the last observation
carriedforwardmethodthatwascommonlyusedatthe
time the study was being planned but has fallen out of
favourmorerecently.
62Thismethodisunlikelytohave
influenced the results, given the small dropout rate (8/
120participants,7%)andthefactthatwefoundsimilar
outcomes when we used generalised estimating equa-
tions to fit population averaged models to the known
scores.
Conclusions and practice implications
Our study showed that the particular manual therapy
and home exercise programme tested conferred no
additional benefit immediately after treatment com-
pared with a realistic placebo in middle aged to older
adults with chronic rotator cuff disease. However,
given evidence of significantly greater improvements
withactivetreatmentatfollow-upinoneoftheprimary
outcomesandinseveralsecondaryoutcomes,theben-
efits of manual therapy and exercise may accrue over
time.Physiotherapyinterventionsmayalsobeofmore
valueforimprovingshoulderfunctionthanpainperse
in this population. Clinicians should thus establish
whether the patient’s primary presenting problem is
pain, impaired function, or both. If pain is a major fac-
tor,thenothertreatmentsthatreducepain,suchascor-
ticosteroid injections, may be more appropriate. If
both pain and loss of function are factors, then drugs
or other pain relieving treatments may be needed in
combinationwithmanualtherapyandexercisetoade-
quately treat all facets. To facilitate adherence, clini-
cians should advise patients that the effects of manual
therapyandexercisearenotnecessarilyimmediatebut
may take several months before they are evident.
Furtherresearchisneededtoevaluatetheeffectiveness
of different physiotherapy treatment regimens and
whether the combination of drug treatment with
physiotherapy leads to greater benefits in people with
mild to moderate chronic rotator cuff disease.
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